Skip to main content
. 2023 Nov 16;12(11):12379. doi: 10.1002/jev2.12379

FIGURE 1.

FIGURE 1

Schematic illustration of fusion HAC NVs for dual‐targeting immune checkpoint blockade therapy. Intravenously injected fusion HAC NVs can distribute to tumour microenvironment and simultaneously block SIRPα/CD47 innate immune pathway and PD‐1/PD‐L1 adaptive immune pathway, promote phagocytosis of macrophages as well as T‐cell antitumour immunity leading to tumour suppression.